GSK PLC closed 15.77% below its 52-week high of £18.24, which the company reached on May 16th.
NEW YORK CITY, NY / ACCESS Newswire / March 16, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds ...
Zacks Investment Research on MSN3d
Why GSK (GSK) is a Top Momentum Stock for the Long-TermFor new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...
Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.
The founders of Bugworks Research are attempting to bring to market a new class of antibiotics--a first in almost half a ...
The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in ...
After a year of controversy and complaints, Sen. Elizabeth Warren is asking a federal watchdog to investigate GSK over its ...
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation studies showing zero cases of HIV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback